|
|
|
|
|
|
WP5 - Systems Biology and Bioinformatics
CDG & Allies - Professionals and Patient Associations
International Network (CDG & Allies-PPAIN)
WG CDG & Biomedical Bioinformatics
|
WG CDG & Computational biology/chemistry
|
WG CDG & Metabolomics
|
WG CDG & Systems Biology
|
Working Group (WG) CDG & Systems Biology
Working Group Leader (WGL): Anaxomics, Systems Biology Solutions Company
About Anaxomics
Anaxomics is a Systems Biology Solutions company. Systems biology is a multidisciplinary approach that integrates and interconnects genes, proteins, and biochemical reactions, thus achieving a better comprehension about the complex cellular and physiological processes and mechanisms.
|
Anaxomics has developed several technological innovations, including their proprietary Therapeutic Performance Mapping System (TPMS) and Drug-to-Target and Target Profiling Technologies. Currently, they are able to perform high-quality services which accelerate discovery, improve the quality of research and reduce costs.
|
Their fields of work include: Mechanisms of Action/System Biology analysis of high-throughput data/Disease-to-target discovery/Drug-to-target and off-target discovery/Clinical safety and efficacy profile.
The Portuguese Association for CDG (APCDG) and Anaxomics Biotech announce strategic partnership in Congenital Disorders of Glycosylation (CDG).
To know more about this collaboration, read our press release below:
| press_release_anaxomics.pdf |
About Vanessa Ferreira
From her unique perspective of being a sister of a patient with a rare disease named Congenital Disorders of Glycosylation (CDG) and Cell Biologist, Vanessa founded the Portuguese CDG Association and other Rare Metabolic Disorders (APCDG-DMR).
|
Vanessa’s personal journey with her sister, combined with the community needs, have been the impetus to focus the APCDG activities.
Vanessa received a bachelor’s degree in Biological Sciences from Badajoz University (Spain). She holds a PhD (Sc.D.) in Cell and Developmental Biology from the Center for Genomic Regulation, University of Pompeu Fabra, Biomedical Research Park in Barcelona (PRBB). In 2014, she completed her background with an International MBA from IAE de Paris, Sorbonne Graduate Business School. |
Any student, research groups, researchers, clinicians, patient organisations or other stakeholders who would like to become more involved within this project, are most welcome to get in touch to discuss possible future opportunities and collaborations. Fulfill the contact form available below:
Future opportunities and collaborations:
Support our research, advocacy, awareness and education efforts now!
|
Our work is publicly available to help the CDG community and related rare disease communities. Importantly, we do not receive government funding. We rely solely on donations in order to continue our projects. Consider to make a donation using Paypal, debit or credit card or bank transfer. |
|
